早期乳腺癌治疗后持续的淋巴细胞减少
Sustained lymphocyte decreases after treatment for early breast cancer
影响因子:7.60000
分区:医学2区 Top / 肿瘤学2区
发表日期:2024 Oct 21
作者:
Julia Dixon-Douglas, Balaji Virassamy, Kylie Clarke, Michael Hun, Stephen J Luen, Peter Savas, Courtney T van Geelen, Steven David, Prudence A Francis, Roberto Salgado, Stefan Michiels, Sherene Loi
摘要
越来越多地认识到适应性免疫在早期乳腺癌的长期结局中的作用。标准（NEO）辅助化疗可能会对免疫细胞产生不利影响。我们对一家单个机构的早期乳腺癌接受了200名患者（NEO）辅助化学疗法的全血计数（FBC）的回顾性纵向研究（FBC）。分析了从预处理到12个月的四个时间点的FBC结果。针对匹配的治疗前和化学后血液单核细胞样品的患者进行了流式细胞仪。观察到化学疗法12个月的绝对淋巴细胞计数显着降低（P <0.01），最明显的绝经前患者（n = 73; p <0.01），接受剂量加密化学疗法治疗方案（n = 60; p <0.01）和接受辅助辅助辅助放射疗法（N = N = 147），患者接受了剂量加密的化学疗法。在绝经前患者中，观察到化学后CD4+ T细胞子集的显着变化。需要进一步的研究，包括长期临床结果，以有意义地改善长期的抗肿瘤免疫力。
Abstract
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal study of full blood counts (FBC) of 200 patients receiving (neo)adjuvant chemotherapy for early breast cancer at a single institution. FBC results at four time points from pre-treatment to 12 months post-chemotherapy were analysed. Flow cytometry was performed for patients with matched pre- and post-chemotherapy peripheral blood mononuclear cell samples. A significant decrease in absolute lymphocyte count at 12 months post-chemotherapy was observed (p < 0.01), most pronounced in pre-menopausal patients (n = 73; p < 0.01), patients receiving dose-dense chemotherapy regimens (n = 60; p < 0.01) and patients receiving adjuvant radiotherapy (n = 147, p < 0.01). In pre-menopausal patients, significant changes in CD4+ T cells subsets post-chemotherapy were observed. Further investigation, including long-term clinical outcomes, is needed to meaningfully improve long-term anti-tumour immunity.